Nalidixic Acid use while Breastfeeding
Drugs containing Nalidixic Acid: NegGram
Nalidixic Acid Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited information indicates that maternal doses of nalidixic acid up to 2 grams daily produce low levels in milk and would usually not be expected to cause any adverse effects in breastfed infants. However, other agents may be preferred, especially while nursing a newborn or preterm infant.
Maternal Levels One paper reported old, unpublished data obtained from the manufacturer in which a breastmilk concentration of 2 mg/L was found at an unspecified time in 4 women taking 1 gram orally 4 times daily.
Thirteen lactating women were given 2 grams of nalidixic acid as a single dose between the third and eighth day postpartum. The average concentration of nalidixic acid in milk during the first four-hour collection period was 0.64 mg/L (range 0.3 to 1.1 mg/L); concentration in milk from other collection periods were as follows: 0.43 mg/L at 4 to 7 hours; 0.2 mg/L at 7 to 10.5 hours; 0.1 mg/L at 10.5 to 16 hours and 0.02 mg/L at 16 to 24 hours after the dose. Using the peak milk level data from this study, the authors estimated that an exclusively breastfed infant would receive a maximum of 300 mcg/day with this maternal dosage regimen, or less than 0.3% of an infant dose.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Decreased weight gain, pallor, jaundice occurred in a 16-day-old infant probably caused by hemolytic anemia induced by maternal use of nalidixic acid orally 1 gram four times daily and amobarbital 65 mg orally three times daily. The infant developed jaundice, hyperbilirubinemia, reticulocytosis, eosinophilia, Heinz bodies and other signs of hemolysis 7 days after its mother was started on nalidixic acid. No G-6-PD deficiency or hemoglobin Zurich could be demonstrated.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
1. Belton EM, Jones RV. Haemolytic anaemia due to nalidixic acid. Lancet. 1965;2:691. Letter. PMID: 4158226
2. Traeger A, Peiker G. Excretion of nalidixic acid via mother's milk. Arch Toxicol Suppl. 1980;4:388-90. PMID: 6933944
Nalidixic Acid Identification
CAS Registry Number
- Antiinfective Agents, Urinary
- Antibacterial Agents
LactMed Record Number
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Nalidixic acid use during Pregnancy
- Nalidixic acid Consumer Information
- Breastfeeding Support Group
- Safe Medications during Breastfeeding
- Medicine use while Breastfeeding
- Medicine use during Pregnancy